Allakos Inc.
ALLKDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001564824
Allakos Inc. was delisted in 2025; its insiders filed their last Form 4 on May 19, 2025; 64 institutions reported holding it in 13F filings for Q1 2025, worth $15.4M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Allakos Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Allakos Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| BVF Partners L P | 10% Owner | 0 | May 19, 2025 | 0 |
| BVF Inc | 10% Owner | 0 | May 19, 2025 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| Lampert Mark N | 10% Owner | 0 | May 19, 2025 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 0 | May 19, 2025 | 0 |
| BVF GP Holdings LLC | 10% Owner | 0 | May 19, 2025 | 0 |
| James Steven P | Director | 0 | May 15, 2025 | 0 |
| Andreatta Robert E | Director | – | May 15, 2025 | 0 |
| Radford Harlan Baird | Chief Financial Officer | 0 | May 15, 2025 | 0 |
| Walker Paul Edward | Director | 0Indirect | May 15, 2025 | 0 |
| Alexander Robert | Chief Executive Officer | 0Indirect | May 15, 2025 | 0 |
| Tomasi Adam | President | 0Indirect | May 15, 2025 | 0 |
| Thomas Dolca | Director | – | May 15, 2025 | 0 |
| Ladd Amy L | Director | – | May 15, 2025 | 0 |
| Graham Neil Murray Hamilton | Director | – | May 15, 2025 | 0 |
| Lee Chin Hyok | Chief Medical Officer | 275,046 | Dec 6, 2024 | 0 |
| Paterson Craig A. | Chief Medical Officer | 323,472 | Dec 5, 2023 | 0 |
| Alta Partners VIII, L.P. | 10% Owner | 0 | Aug 18, 2023 | 0 |
| Alta Partners Management VIII, LLC | 10% Owner | 0 | Aug 18, 2023 | 0 |
| Sutherland Everett Rand | Director | – | Aug 3, 2023 | 0 |
| Janney Daniel | Director | 2,546,147Indirect | May 30, 2023 | 0 |
| Fitzgerald Margaret Nell | General Counsel and Secretary | 153,128 | Sep 6, 2022 | 0 |
| McKearn John P | Director | – | May 27, 2022 | 0 |
| Asbury Mark | CLO | 226,935 | Mar 3, 2022 | 0 |
| Holles Natalie C. | Director | – | Oct 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2024 (view filing) | Jun 28 | 4 days | Radford Harlan BairdChief Financial Officer | SSale | −87.1K | $1.01 | −$87.9K | −29.9%204.4K after | |
| Sep 23, 2022 (view filing) | Sep 21 | 2 days | Walker Paul EdwardDirector | PPurchase | +3.98M | $5.02 | +$20.0M | New position3.39M after | 2 lots |
| Sep 23, 2022 (view filing) | Sep 21 | 2 days | Janney DanielDirector, 10% Owner | PPurchase | +475.0K | $5.02 | +$2.38M | +22.9%2.55M after | |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | James Steven PDirector | SSale | −4.00K | $108.12 | −$432.5K | −100.0%0 after |